← Back to Search

Advanced MRI Imaging for Kidney Cancer

N/A
Recruiting
Led By Eric Sigmund, PhD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
eGFR above 30 ml/min/m2
Ages 21 to 85
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to year 1 post-operation
Awards & highlights

Study Summary

This trial uses advanced imaging to assess if a kidney tumor is cancerous and how it may affect kidney function after surgery.

Who is the study for?
This trial is for adults aged 21 to 85 with kidney tumors who are scheduled for a type of surgery called laparoscopic partial nephrectomy. They must have a certain level of kidney function (eGFR above 30) and be able to consent. People with metal or dental implants unsafe in strong magnetic fields, pregnant women, or those with severe claustrophobia cannot join.Check my eligibility
What is being tested?
The study uses advanced MRI scans and a tracer called Tc-99m Pentetate to assess the nature of kidney tumors and predict changes in kidney function after part of the kidney is surgically removed.See study design
What are the potential side effects?
MRI scans are generally safe but can cause discomfort especially if you're claustrophobic. The tracer used may cause mild allergic reactions or discomfort at the injection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney function is above the minimum required level.
Select...
I am between 21 and 85 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to year 1 post-operation
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to year 1 post-operation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Times Lesion Type is Correctly Predicted using IVIM-MRI at Pre-Surgery
Secondary outcome measures
Percentage of Times Post-Surgical Renal Function is Correctly Predicted Using REFMAP-MRI at Pre-Surgery

Trial Design

1Treatment groups
Experimental Treatment
Group I: Renal Mass PatientsExperimental Treatment2 Interventions
Patients will be enrolled for 2 MRI visits. These visits will include an approximately 1 hour research MRI scan and a total of between 3 and 5 hours Tc-99m DTPA scan. In each MRI visit, patients will be scanned for approximately one hour including both standard-of-care clinical sequences and research-based Advanced Diffusion Imaging sequences, on a Prisma 3T MRI scanner. Following the MRI exam or on a day not more than a week after the MRI exam, patients will undergo renal function assessment via Tc-99m DTPA scan and patient's kidneys will be scanned using a gamma camera. Proteinuria will be assessed by standard of care urinalysis of specimens collected at each MRI visit for each patient. Blood test will be performed at each visit to estimate GFR (eGFR) from measurement of serum creatinine.

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,373 Previous Clinical Trials
840,929 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,720 Previous Clinical Trials
7,494,329 Total Patients Enrolled
Eric Sigmund, PhDPrincipal InvestigatorNYU Langone Medical Center
~91 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top